Donor-specific antibody desensitization with daratumumab prior to haematopoietic cell transplant for sickle cell disease: A case report
Br J Haematol
.
2024 Apr;204(4):1540-1544.
doi: 10.1111/bjh.19289.
Epub 2024 Jan 11.
Authors
Binni Kunvarjee
1
,
Gloria Paz Contreras Yametti
2
,
Amanda G Blouin
3
,
Grace E Linder
3
,
P Dayand Borge
3
,
Elena Maryamchik
3
,
Alexandra Budhai
3
,
Gaurav K Gupta
3
,
Andromachi Scaradavou
2
,
Barbara G Spitzer
2
,
Kevin J Curran
2
,
Joseph H Oved
2
,
Andrew C Harris
2
,
Akshay Sharma
4
,
Jaap Jan Boelens
2
,
Maria I Cancio
2
Affiliations
1
Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
2
Pediatric Bone Marrow Transplant and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
3
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
4
Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
PMID:
38212144
PMCID:
PMC11389601
(available on
2025-04-01
)
DOI:
10.1111/bjh.19289
No abstract available
Publication types
Case Reports
Letter
MeSH terms
Anemia, Sickle Cell* / therapy
Antibodies, Monoclonal / therapeutic use
HLA Antigens
Hematopoietic Stem Cell Transplantation*
Humans
Tissue Donors
Substances
daratumumab
Antibodies, Monoclonal
HLA Antigens
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States
P30 CA008748/NH/NIH HHS/United States